Tag: Lagevrio

In late 2021, the U.S. Food and Drug Administration (FDA) authorized the first oral antiviral treatments for COVID-19, Paxlovid and Lagevrio, for high-risk patients to help prevent severe illness. Understanding **what is the difference between Paxlovid and Lagevrio** is crucial for patients, as these medications vary significantly in their mechanisms of action, overall effectiveness, potential for drug interactions, and eligibility criteria.

Paxlovid, an oral antiviral, reduced the risk of COVID-19 hospitalization or death by 86% in one clinical trial. However, due to significant drug interactions or other contraindications, some patients require an alternative. So, what is a substitute for Paxlovid?

According to the Centers for Disease Control and Prevention, Paxlovid is the preferred oral antiviral for high-risk COVID-19 patients, but a patient's specific health conditions and medications may make an alternative necessary. For these patients, understanding **what is the alternative to Paxlovid?** is vital for ensuring effective and safe treatment.